Progressive inflammatory neuropathy

WikiDoc Resources for Progressive inflammatory neuropathy
Articles
Most recent articles on Progressive inflammatory neuropathy Most cited articles on Progressive inflammatory neuropathy Review articles on Progressive inflammatory neuropathy Articles on Progressive inflammatory neuropathy in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Progressive inflammatory neuropathy Images of Progressive inflammatory neuropathy Photos of Progressive inflammatory neuropathy Podcasts & MP3s on Progressive inflammatory neuropathy Videos on Progressive inflammatory neuropathy
Evidence Based Medicine
Cochrane Collaboration on Progressive inflammatory neuropathy Bandolier on Progressive inflammatory neuropathy TRIP on Progressive inflammatory neuropathy
Clinical Trials
Ongoing Trials on Progressive inflammatory neuropathy at Clinical Trials.gov Trial results on Progressive inflammatory neuropathy Clinical Trials on Progressive inflammatory neuropathy at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Progressive inflammatory neuropathy NICE Guidance on Progressive inflammatory neuropathy NHS PRODIGY Guidance FDA on Progressive inflammatory neuropathy CDC on Progressive inflammatory neuropathy
Books
Books on Progressive inflammatory neuropathy
News
Progressive inflammatory neuropathy in the news Be alerted to news on Progressive inflammatory neuropathy News trends on Progressive inflammatory neuropathy
Commentary
Blogs on Progressive inflammatory neuropathy
Definitions
Definitions of Progressive inflammatory neuropathy
Patient Resources / Community
Patient resources on Progressive inflammatory neuropathy Discussion groups on Progressive inflammatory neuropathy Patient Handouts on Progressive inflammatory neuropathy Directions to Hospitals Treating Progressive inflammatory neuropathy Risk calculators and risk factors for Progressive inflammatory neuropathy
Healthcare Provider Resources
Symptoms of Progressive inflammatory neuropathy Causes & Risk Factors for Progressive inflammatory neuropathy Diagnostic studies for Progressive inflammatory neuropathy Treatment of Progressive inflammatory neuropathy
Continuing Medical Education (CME)
CME Programs on Progressive inflammatory neuropathy
International
Progressive inflammatory neuropathy en Espanol Progressive inflammatory neuropathy en Francais
Business
Progressive inflammatory neuropathy in the Marketplace Patents on Progressive inflammatory neuropathy
Experimental / Informatics
List of terms related to Progressive inflammatory neuropathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords:

Overview

Progressive inflammatory neuropathy (PIN) is a disease that was identified in a report, released on January 31, 2008, by the Centers for Disease Control and Prevention. The first known outbreak of this neuropathy was in southeastern Minnesota in the United States. The disease was reported among pig slaughterhouse workers. It is believed these workers might have contracted the disease through inhaling aerosols from pig brains blown through compressed-air devices and that "worker exposure to aerosolized pig neural protein might have induced an autoimmune-mediated peripheral neuropathy."

Historical Perspective

• [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

• [Disease name] may be caused by either [cause1], [cause2], or [cause3].
• [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
• There are no established causes for [disease name].

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

Symptoms include acute paralysis, weakness, and numbness. The symptoms are similar to those for Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].